Roche Oseltamivir Flu Pill Heads To September Advisory Committee
Executive Summary
Roche expects its oseltamivir flu drug to be on FDA's Antiviral Drugs Advisory Committee agenda in September. A meeting of the committee is tentatively scheduled for Sept. 13-15.